Individualized treatment with infliximab therapy in children with Crohn’s disease support shorter time intervals between infusions

نویسندگان

  • M. Sommar
  • S. Eksborg
  • H. Hildebrand
  • L. Grahnquist
چکیده

OBJECTIVES To study the effect of an individualized treatment approach with regard to dosage intervals between infliximab infusions on the clinical outcome of pediatric Crohn's disease (CD). PATIENTS AND METHODS A retrospective analysis of medical records of all pediatric patients with CD who had been treated with infliximab between 1999 and 2007 in two Swedish counties, where an individualized treatment approach had been applied. RESULTS Twenty-nine patients were included in the study. The number of infusions varied from 2 to 47 (median: 8). Nineteen patients received more than 5 infusions and 13 patients received more than 10 infusions. Most of the patients did not stay in remission when the dosage interval was 8 weeks or longer. CONCLUSIONS An individualized treatment approach, based on the physician's desire to treat, resulted in shorter dosage intervals than 8 weeks between infliximab infusions in a majority of pediatric patients with CD. The retrospective design of the study must be taken into account when interpreting the results.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Isolated cutaneous Crohn’s disease: A case report

This case report describes a patient with cutaneous signs in the genital and peri-anal region suspicious of Crohn’s disease without any intestinal symptom or sign. Inflammatory bowel disease can be associated with some cutaneous signs. However, in this paper, we report a patient with isolated cutaneous Crohn’s disease which is very rare (less than 100 case reports across the world). Our patient...

متن کامل

INFLAMMATORY BOWEL DISEASE Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease

Background and aims: To verify whether targeting defective mucosal T cell death underlies the sustained therapeutic benefit of infliximab in Crohn’s disease, we explored its in vivo proapoptotic effect after 10 weeks of treatment, and its in vitro killing activity on lamina propria T cells (LPT) and peripheral blood T cells (PBT), both isolated from Crohn’s disease patients. Methods: Endoscopic...

متن کامل

Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?

Controlled trials have confirmed the efficacy of two tumour necrosis factor α (TNF-α) antibodies in active Crohn’s disease. In responding patients, the therapeutic effects qualitatively differ from those observed with standard therapy, including corticosteroids and immunosuppressives, and complete clinical remission can be induced in about one third of patients that did not respond to standard ...

متن کامل

Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?

Among the many complications of Crohn’s disease, the development of fistulas is one of the most distressing to patients because it decreases their quality of life and one of the most frustrating to physicians because of the dishearteningly high rate of management failure. Review articles offer complex clinical algorithms and long lists of therapeutic options for fistulizing Crohn’s disease, ran...

متن کامل

Evaluation of Compartment Models for Simulation of Infliximab Depletion

Infliximab is an antibody that is approved for treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. It is important to predict the course of the depletion of Infliximab in the body to time the regular infusions that patients get. The base model is a two-compartment-model and three parameter identification approaches are compared: identification of each infusion p...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 1  شماره 

صفحات  -

تاریخ انتشار 2012